DJIA 18,080.14 21.45 0.12%
NASDAQ 5,092.09 36.02 0.71%
S&P 500 2,117.69 4.76 0.23%
market minute promo

Alkermes, Inc. (NASDAQ: ALKS)

62.26 -1.19 (-1.88%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ALKS $62.26 -1.88%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $63.45
Previous Close $63.45
Daily Range $62.20 - $63.87
52-Week Range $38.49 - $75.17
Market Cap $9.2B
P/E Ratio -302.14
Dividend (Yield) $0.00 (0.0%)
Volume 524,127
Average Daily Volume 1,322,394
Current FY EPS -$1.03

Sector

Healthcare

Industry

Drug Makers

Alkermes, Inc. (ALKS) Description

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Website: http://www.alkermes.com/

News & Commentary

A New Drug Could Halt Weight Gain in Patients Taking These Antipsychotics

Alkermes Plc's ALKS 3831 could help patients that take atypical antidepressants avoid gaining weight.

Next Week In Biotech: Gilead, Celgene Report; PDUFAs For Theravance, The Medicines Co.

First Week of ALKS June 19th Options Trading

Alkermes - The Underappreciated Biopharmaceutical

Midday Update: Stocks Holding On To Slim Gains Ahead of Upcoming Earnings Glut

Health Care Sector Update for 04/13/2015: NEOT, AEZS, REPH

The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Pres

The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Press Releases

Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept Slides on Deal Termination - Analyst Blo

Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept Slides on Deal Termination - Analyst Blog

Alkermes Reports Encouraging Data on Schizophrenia Drug - Analyst Blog

Biogen/AbbVie's MS Drug Zinbryta Under Review in the EU - Analyst Blog

See More ALKS News...

ALKS's Top Competitors

ALKS $62.26 (-1.88%)
Current stock: ALKS
AMGN $167.91 (-0.74%)
Current stock: AMGN
GILD $103.70 (-1.44%)
Current stock: GILD
BIIB $401.71 (-6.64%)
Current stock: BIIB